Joseph Baroldi - 26 Jun 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: EVP, Chief Business Officer
Issuer ticker: IONS
Reported as of: 26 Jun 2026
Net transaction value: -$451,699
SEC form: 4
Accepted by SEC: 30 Jun 2026, 17:48:32 UTC
Prior SEC filing: 30 Apr 2026
Source filing: View source filing
Reporting owner signature: By: Patrick R. O’Neil, attorney-in-fac For: Joseph Baroldi

Key filing fact

Joseph Baroldi filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 30 Jun 2026.

Key facts

This page summarizes Joseph Baroldi's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 Jun 2026, 17:48.

Change

Previous filing in this sequence was filed on 30 Apr 2026.
Current net transaction value: -$451,699.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001813775 Primary reporting owner

Baroldi Joseph

Relationship: EVP, Chief Business Officer
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: By: Patrick R. O’Neil, attorney-in-fac For: Joseph Baroldi
Signature date: 30 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,866
Change %: +83%
Price: $56.78^*
Shares after: 8,535
Date: 26 Jun 2026
Ownership: by Spouse

IONS transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,769
Change %: +21%
Price: $32.60^*
Shares after: 10,304
Date: 26 Jun 2026
Ownership: by Spouse

IONS transaction

Common Stock

Sale

Transaction value: $451,699
Shares: -5,635
Change %: -55%
Price: $80.16
Shares after: 4,669
Date: 26 Jun 2026
Ownership: by Spouse
Footnotes: F1, F2

IONS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 48,522
Date: 26 Jun 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -1,769
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 26 Jun 2026
Ownership: by Spouse
Underlying class: Common Stock
Underlying amount: 1,769
Exercise price: $32.60

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -3,866
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 26 Jun 2026
Ownership: by Spouse
Underlying class: Common Stock
Underlying amount: 3,866
Exercise price: $56.78

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting persons spouse on November 25, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.52 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.